跳至主要内容
临床试验/CTIS2024-511711-21-00
CTIS2024-511711-21-00进行中(未招募)1 期

ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial

Amsterdam UMC Stichting0 个研究点目标入组 38 人开始时间: 2024年3月15日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
38

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Histologically or cytologically confirmed stage III (non-N3) NSCLC (TNM 8th edition), before start of chemoradiotherapy, In case of suspected N2-disease, mediastinal invasive staging (EUS, EBUS and/or mediastinoscopy) to prove N2 involvement before start of concurrent CRT is mandatory., Initial MDT recommendation for a non-surgical treatment comprising CRT followed by durvalumab

排除标准

  • Patients with TxN3 or M1 disease, The use of any CRT schemes other than those in ESMO recommendations (platinum doublet, 30 once-daily fractions of 2 Gy), Patients deemed inoperable based on cardiopulmonary function tests or comorbidity

研究者

相似试验

ChemoRadiotherapy with Or Without surgery followed... | 临床试验